Skip to main
COR

Cencora Inc (COR) Stock Forecast & Price Target

Cencora Inc (COR) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 54%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Cencora is a strong competitor in the US pharmaceutical wholesale industry, with a dominant market share alongside McKesson and Cardinal Health. The recent acquisition of Alliance Healthcare has also expanded its presence in Europe, demonstrating its commitment to international growth. Though it lacks the high-growth, high margin businesses of its competitors, Cencora's leading specialty distribution, particularly in the retina and oncology MSO space, insulates it from PBM steerage risk. Additionally, its expansion into patient support and data analytics services positions the company for continued growth and adaptability in a changing healthcare landscape. The potential for biosimilar launches and upcoming patent cliffs also presents opportunities for margin expansion. However, potential regulatory changes and scrutiny could negatively impact distribution margins and fee structures, and COR's lack of differentiation from its peers may limit its upside potential. Based on these factors, the analyst initiates coverage with a Sector Perform rating and a price target of $330, reflecting a slight premium to its current PE multiples.

Bears say

Cencora is facing intensified FTC scrutiny and competition from McKessonand Cardinal Health in the US pharmaceutical wholesale industry, with the recent sale ofMWI Animal Health to Covetrus putting further pressure on regulatory hurdles and market share concentration. While the company has expanded internationally and into services such as commercialization and global specialty drug logistics, its lack of diversified growth drivers and potential risks from changes to pharmaceutical pricing and reimbursement policies add to our negative outlook.

Cencora Inc (COR) has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 54% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cencora Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cencora Inc (COR) Forecast

Analysts have given Cencora Inc (COR) a Buy based on their latest research and market trends.

According to 13 analysts, Cencora Inc (COR) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $368.46, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $368.46, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cencora Inc (COR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.